WO1997040073A2 - BIOLOGISCH AKTIVER EIWEISSSTOFF - KOLLAGENFRAGMENT HF-COLL-18/514cf - ZUR HEMMUNG DES WACHSTUMS VON TUMOREN UND VON GEFÄSSWUCHERUNGEN - Google Patents
BIOLOGISCH AKTIVER EIWEISSSTOFF - KOLLAGENFRAGMENT HF-COLL-18/514cf - ZUR HEMMUNG DES WACHSTUMS VON TUMOREN UND VON GEFÄSSWUCHERUNGEN Download PDFInfo
- Publication number
- WO1997040073A2 WO1997040073A2 PCT/EP1997/002012 EP9702012W WO9740073A2 WO 1997040073 A2 WO1997040073 A2 WO 1997040073A2 EP 9702012 W EP9702012 W EP 9702012W WO 9740073 A2 WO9740073 A2 WO 9740073A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ser
- ala
- leu
- coll
- arg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a peptide (protein) with the ability to influence the growth of cells.
- the collagen fragment HF-C0LL-18 / 514cf, as well as fragments and / or derivatives derived from it, and a medicinal product containing the natural and synthetic peptides can be used for diagnostic or therapeutic purposes.
- the present invention thus relates to a new peptide, the HF-COLL-18 / 514cf, its production, medicaments containing it, and preparations containing it and its use therefor, and also its natural and pharmacologically contractual 1 -
- the blood peptide HF-COLL-18 / 514cf has the amino acid sequence: Val -Ala -Leu -Asn -Ser -Pro-Leu- Ser-Gly-Gly-Met-Arg-Gly-Ile -Arg -Gly- Ala-Asp-Phe -Gln-Cys-Phe-Gln-Gln-Ala-Arg-Ala -Val -Gly-Leu-Ala-Gly- Thr- Phe- Arg- Ala- Phe - Leu - Ser -Ser- Ar Q- Leu-Gin - Asr> -Leu-Tyr- Ser -Ile - Val -Arg -Arg -Ala -Asp- Arg- Ala- Ala - Val - Pro- II e- Val -Asn-Leu-L ⁇ s -Asp- Glu-Leu-Leu- Phe-Pro-Ser-
- the pharmaceutical preparation can also contain auxiliaries that are due to filling technology, contribute to the solubility, stability or sterility of the drug or increase the efficiency of absorption into the body.
- auxiliaries that are due to filling technology, contribute to the solubility, stability or sterility of the drug or increase the efficiency of absorption into the body.
- the use of the lyophilized form taken with mannitol in sterile ampoules for dissolution in physiological saline and / or infusion solutions for repeated single injection and / or continuous infusion in amounts of 30 micrograms to 30 milligrams of pure HF-COLL-18 / 514cf pro Therapy unit is beneficial.
- the daily dose to be administered for HF-COLL-18 / 514cf depends on the indication and use of certain derivatives. At i.v./i.m. Injection is in the range from 100 to 1200 units ( ⁇ g) / day, with daily subcutaneous injection preferably at 300 to 2400 units ( ⁇ g) / day.
- the peptide HF-COLL-18 / 514cf according to the invention is characterized in that it is also particularly suitable for long-term JPherapy for tumor diseases or other diseases which are characterized by uncontrolled vascular growth, and does not trigger an immune reaction in the case of long-term treatment. That invented
- the preparation according to the invention is particularly suitable for combination therapy with chemotherapy or radiation therapy or in connection with chemotherapy or radiation therapy for cancer.
- the medicament according to the invention is suitable for the treatment of diseases of the human organism, in particular in connection with vascular growths, cancer diseases, diseases involving the cardiovascular and nervous systems, diseases involving the intugement and the sensory organs, in particular the eye.
- Example 1 Isolation and characterization of circulating HF-COLL-18 / 514cf from human hemofiltrate
- Hemofiltrate which is obtained in large quantities in the treatment of kidney insufficient patients and all plasma components up to a molecular size of about 20, was used as the starting material. Contains 000 daltons.
- Eluent A water with 10MM HC1
- Eluent B methanol with 10 mM HC1 gradient: 0 - 50% eluent B 28.57 min 50 - 95% eluent B 61.43 min 95% eluent B 5.71 min flow rate: 35 ml / min fractions: 50 ml or 1 , 43 min detection: 230 nm and 280 nm
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97921682A EP0896584A2 (de) | 1996-04-22 | 1997-04-22 | BIOLOGISCH AKTIVER EIWEISSSTOFF - KOLLAGENFRAGMENT HF-COLL-18/514cf - ZUR HEMMUNG DES WACHSTUMS VON TUMOREN UND VON GEFÄSSWUCHERUNGEN |
AU27665/97A AU2766597A (en) | 1996-04-22 | 1997-04-22 | Biologically active protein (collagen fragment hf-coll-18/514cf) for inhibiting the growth of tumours and capillary profilerations |
JP09537737A JP2000511511A (ja) | 1996-04-22 | 1997-04-22 | 腫瘍成長阻害及び毛細管増殖のための生物学的活性タンパク質、コラーゲンフラグメントHF―COLL―18/514cf |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19615710A DE19615710A1 (de) | 1996-04-22 | 1996-04-22 | Verfahren zur Gewinnung und Anwendung eines biologisch aktiven Eiweisstoffes - Kollagenfragment HF-COLL-18/514cf - in partiell aufgereinigter und synthetischer Form aus Körperflüssigkeiten zur Beeinflussung des Zellwachstums und der Diagnose von Kollagenerkrankungen sowie der Osteoporose |
DE19615710.2 | 1996-04-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997040073A2 true WO1997040073A2 (de) | 1997-10-30 |
WO1997040073A3 WO1997040073A3 (de) | 1997-12-24 |
Family
ID=7791888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/002012 WO1997040073A2 (de) | 1996-04-22 | 1997-04-22 | BIOLOGISCH AKTIVER EIWEISSSTOFF - KOLLAGENFRAGMENT HF-COLL-18/514cf - ZUR HEMMUNG DES WACHSTUMS VON TUMOREN UND VON GEFÄSSWUCHERUNGEN |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0896584A2 (de) |
JP (1) | JP2000511511A (de) |
AU (1) | AU2766597A (de) |
DE (1) | DE19615710A1 (de) |
WO (1) | WO1997040073A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000017240A1 (de) * | 1998-09-21 | 2000-03-30 | Haemopep Pharma Gmbh | Hmw-endostatin zur hemmung des wachstums von tumoren und von gefässwucherungen und zur diagnose von gefäss- und tumorerkrankungen |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999048924A1 (en) * | 1998-03-24 | 1999-09-30 | The Children's Medical Center Corporation | Endostatin derived peptides with anti-angiogenic and anti-cancer activity |
ITMI20010394A1 (it) * | 2001-02-27 | 2002-08-27 | Univ Degli Studi Milano | Peptidi ad attivita' antiangiogenica |
GB0114419D0 (en) * | 2001-06-13 | 2001-08-08 | Mars Uk Ltd | Health food |
WO2004050125A1 (ja) * | 2002-12-03 | 2004-06-17 | Koken Co.,Ltd. | 腫瘍細胞の増殖及び/又は浸潤の抑制剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3633797A1 (de) * | 1986-10-03 | 1988-04-07 | Forssmann Wolf Georg | Verfahren zur gewinnung von biologisch aktiven eiweissen (peptiden) aus menschlichem und tierischem blut (bzw. anderen koerperfluessigkeiten) |
WO1993016716A1 (en) * | 1992-02-24 | 1993-09-02 | Northwestern University | Method and composition for inhibiting angiogenesis |
WO1997015666A1 (en) * | 1995-10-23 | 1997-05-01 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
-
1996
- 1996-04-22 DE DE19615710A patent/DE19615710A1/de not_active Withdrawn
-
1997
- 1997-04-22 AU AU27665/97A patent/AU2766597A/en not_active Abandoned
- 1997-04-22 WO PCT/EP1997/002012 patent/WO1997040073A2/de not_active Application Discontinuation
- 1997-04-22 EP EP97921682A patent/EP0896584A2/de not_active Withdrawn
- 1997-04-22 JP JP09537737A patent/JP2000511511A/ja not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3633797A1 (de) * | 1986-10-03 | 1988-04-07 | Forssmann Wolf Georg | Verfahren zur gewinnung von biologisch aktiven eiweissen (peptiden) aus menschlichem und tierischem blut (bzw. anderen koerperfluessigkeiten) |
WO1993016716A1 (en) * | 1992-02-24 | 1993-09-02 | Northwestern University | Method and composition for inhibiting angiogenesis |
WO1997015666A1 (en) * | 1995-10-23 | 1997-05-01 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
Non-Patent Citations (3)
Title |
---|
M.S. O'REILLY ET AL.: "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth" CELL, Bd. 88, Nr. 2, 24.Januar 1997, NA US, Seiten 277-285, XP002044657 * |
OH S P ET AL: "CLONING OF CDNA AND GENOMIC DNA ENCODING HUMAN TYPE XVIII COLLAGEN AND LOCALIZATION OF THE ALPHA1(XVIII) COLLAGEN GENE TO MOUSE CHROMOSOME 10 AND HUMAN CHROMOSOME 21" GENOMICS, Bd. 19, Nr. 3, Februar 1994, Seiten 494-499, XP000615991 in der Anmeldung erw{hnt * |
O'REILLY M S ET AL: "Endogenous inhibitors of angiogenesis." 87TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, WASHINGTON, D.C., USA, APRIL 20-24, 1996. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 37 (0). 1996. 669. ISSN: 0197-016X, M{rz 1996, XP002022627 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000017240A1 (de) * | 1998-09-21 | 2000-03-30 | Haemopep Pharma Gmbh | Hmw-endostatin zur hemmung des wachstums von tumoren und von gefässwucherungen und zur diagnose von gefäss- und tumorerkrankungen |
Also Published As
Publication number | Publication date |
---|---|
AU2766597A (en) | 1997-11-12 |
EP0896584A2 (de) | 1999-02-17 |
WO1997040073A3 (de) | 1997-12-24 |
DE19615710A1 (de) | 1997-10-23 |
JP2000511511A (ja) | 2000-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0763061B1 (de) | Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung | |
EP0167575B1 (de) | Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung | |
EP0209061B1 (de) | Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel | |
DE69736712T2 (de) | Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden | |
DE3100974C2 (de) | ||
EP0497915B1 (de) | hPTH-FRAGMENT-(1-37), SEINE HERSTELLUNG, DIESES ENTHALTENDE ARZNEIMITTEL UND SEINE VERWENDUNG | |
EP0158986A2 (de) | Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel | |
DE19908041A1 (de) | Kovalent verbrückte Insulindimere | |
WO1999032620A9 (de) | Insulin-like growth factor binding protein fragmente und ihre verwendung | |
DE60207043T2 (de) | Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese | |
EP2217619B1 (de) | Zyklisches, cystein-freies protein | |
EP1299541B1 (de) | Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen | |
DE60124915T2 (de) | Synthetische peptide gegen neurologische krankheiten | |
DE69630583T2 (de) | Peptide, bronchodilator und den blutstrom verbesserndes mittel | |
WO1997040073A2 (de) | BIOLOGISCH AKTIVER EIWEISSSTOFF - KOLLAGENFRAGMENT HF-COLL-18/514cf - ZUR HEMMUNG DES WACHSTUMS VON TUMOREN UND VON GEFÄSSWUCHERUNGEN | |
AT400444B (de) | Verfahren zur herstellung von oncostatin m | |
EP1959013A1 (de) | Humanes zirkulierendes Virus inhibierendes Peptid (VIRIP) und seine Verwendung | |
DE19543628A1 (de) | Humanes, im Blut zirkulierendes Peptid mit insulinotroper Wirkung (GCAP-II-(89-112), (Guanylyl Cyclase C Aktivierendes Peptid II) und seine GCAP-Analoga, insbesondere das GCAP-I-(99-115), seine Anwendung als pharmakologischer Wirkstoff und Benutzung seines Wirkungsprinzipes zur Bereitstellung neuer GC-C-abhängiger insulinotroper Wirkstoffe | |
EP1023445B1 (de) | Cadherin derived growth factor und seine verwendung | |
WO2000017240A1 (de) | Hmw-endostatin zur hemmung des wachstums von tumoren und von gefässwucherungen und zur diagnose von gefäss- und tumorerkrankungen | |
DE4244565A1 (de) | Verfahren und Anwendung des LPAP (Lymphocytoma Proliferation Activating Peptide | |
DE4309815A1 (de) | Verfahren zur Gewinnung und Anwendung des Guanylatzyklavaktivierenden Peptid I (GAP-I) | |
WO1997006258A2 (de) | cDNA-SEQUENZ UND DARAUS ABGELEITETE AMINOSÄURESEQUENZ DES VORLÄUFERPROTEINS VON HUMANEM GCAP-II/UROGUANYLIN SOWIE AMINOSÄURESEQUENZ DES IM HUMANEN BLUT ZIRKULIERENDEN FRAGMENTES | |
DE19951824A1 (de) | Humanes zirkulierendes Insulin-like Growth Factor Binding Protein-3 Fragment und seine Verwendung | |
WO1995003410A2 (de) | Ein für guanylatcyclase activating peptide i (gcap-i) kodierendes gen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KG KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KG KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US GH |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997921682 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997921682 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997921682 Country of ref document: EP |